LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jinyang, Dong, Feng, He, You, Xia, Xianyou, Cheng, Fangling, Chen, Sui, Hou, Xiaoshuang, Zhang, Po, Liu, Guohao, Li, Ying, Gao, Qian, Dong, Minhai, Li, Ting, Li, Wei, Xiao, Qungen, Li, Xiaopeng, Yu, Xingjiang, Xi, Guifa, Guo, Dongsheng, Wu, Xudong, Wang, Baofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472135/
https://www.ncbi.nlm.nih.gov/pubmed/36096529
http://dx.doi.org/10.1136/jitc-2021-004452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472135/
https://www.ncbi.nlm.nih.gov/pubmed/36096529
http://dx.doi.org/10.1136/jitc-2021-004452

Ejemplares similares